Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07121946 · ClinicalTrials.gov registry record · Phase 1
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
A Phase 1 study of Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL), sponsored by LTZ Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
- 5
- Study locations
NCT07121946 is a Phase 1 study of Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL) that is actively recruiting participants, run by LTZ Therapeutics. The registered enrollment target is 42 participants, below the 528-participant average among 10 other Follicular Lymphoma (FL) trials with a reported enrollment target (92% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT07121946, a Phase 1 study of Follicular Lymphoma (FL) and Mantle Cell Lymphoma (MCL), is actively recruiting participants, sponsored by LTZ Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Conditions Studied
Interventions
- BIOLOGICAL LTZ-301
Study Locations (5)
California
- City of Hope - Duarte
Missouri
- Washington University School of Medicine - St Louis
New York
- Roswell Park Cancer Institute - Buffalo
Tennessee
- Tennessee Oncology - Nashville
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2026-01-29 |
| Est. Completion | 2028-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07121946
The ClinicalTrials.gov registry entry for NCT07121946 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 528-participant average among 10 other Follicular Lymphoma (FL) trials with a reported enrollment target (92% lower). The listed sponsor is LTZ Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Follicular Lymphoma (FL) appearing as the primary indexed condition, and to 1 intervention - of which LTZ-301 is the first listed.
NCT07121946 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Missouri, New York.
Frequently Asked Questions
What is clinical trial NCT07121946 about?
NCT07121946 is a clinical study titled "This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma". This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-...
What is the current status of trial NCT07121946?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2026-01-29. Estimated completion is 2028-02.
What conditions does trial NCT07121946 study?
This clinical trial studies the following conditions: Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), DLBCL - Diffuse Large B Cell Lymphoma, Marginal Zone Lymphoma (MZL), Non-Hodgkin Lymphoma Refractory/ Relapsed.
What interventions are being tested in trial NCT07121946?
The interventions under investigation include: LTZ-301 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07121946?
This trial is sponsored by LTZ Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07121946 being conducted?
This trial has 5 study locations across California, Missouri, New York, Tennessee, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma (FL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
RECRUITING · Phase 1
-
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies
COMPLETED · Phase 1
-
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RECRUITING · Phase 2
-
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.